Share price · CAPR
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when CAPR's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 11 Nov 2026+26.5%
- 14 Aug 2026+58.0%
- 30 Jul 2026-36.2%
- 27 Jul 2026-64.5%
- 29 Jun 2026-10.0%
- 26 Jun 2026-13.0%
- 8 May 2026-10.5%
- 13 Apr 2026+10.7%
Nothing announced by CAPR that day or the session before.
- 10 Mar 2026+9.0%
- 6 Mar 2026+8.1%
Nothing announced by CAPR that day or the session before.
Share of unusual movement by asset
For each asset, the share of CAPR's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Cardiac cell therapyCell therapy | Heart FailureDuchenne Muscular Dystrophy |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(7)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $30M | $45M+ $153M short-term inv. | $43M-$36M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $29M | $21M+ $217M short-term inv. | $41M-$31M operating cash flow | report ↗ |
| 2026-Q1 | — | $27M | $105M+ $173M short-term inv. | $34M-$29M operating cash flow | report ↗ |
| 2025-Q3 | — | $20M | $20M+ $79M short-term inv. | $25M-$20M operating cash flow | report ↗ |
| 2025-Q2 | — | $22M | $23M+ $100M short-term inv. | $26M-$20M operating cash flow | report ↗ |
| 2025-Q1 | — | $19M | $29M+ $116M short-term inv. | $24M-$6.4M operating cash flow | report ↗ |
| 2024-Q3 | $2.3M | $12M | $68M+ $17M short-term inv. | $13M-$12M operating cash flow | report ↗ |
| 2024-Q2 | $4.0M | $13M | $11M+ $19M short-term inv. | $11M-$12M operating cash flow | report ↗ |
| 2024-Q1 | $4.9M | $11M | $6.2M+ $34M short-term inv. | $9.8M-$1.3M operating cash flow | report ↗ |
| 2023-Q3 | $6.2M | $10M | $9.0M+ $20M short-term inv. | $6.4M-$8.8M operating cash flow | report ↗ |
| 2023-Q2 | $3.9M | $8.8M | $9.8M+ $28M short-term inv. | $7.4M-$9.4M operating cash flow | report ↗ |
| 2023-Q1 | $3.0M | $7.7M | $11M+ $35M short-term inv. | $7.8M$4.2M operating cash flow | report ↗ |
| 2022-Q3 | $1.6M | $5.5M | $8.4M+ $38M short-term inv. | $6.4M-$5.7M operating cash flow | report ↗ |
| 2022-Q2 | — | $5.0M | $16M+ $35M short-term inv. | $7.1M-$6.5M operating cash flow | report ↗ |
| 2022-Q1 | — | $5.1M | $58M | $7.8M$24M operating cash flow | report ↗ |
| 2021-Q3 | — | $2.5M | $41M | $3.9M-$3.3M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0 | $84M | $288M+ $30M short-term inv. | $26M-$70M operating cash flow | report ↗ |
Capricor reported full-year 2025 revenue of $0M, down 100.0% YoY from $22.27M, with R&D spend of $84.45M, up 69.0% YoY. Cash, cash equivalents and marketable securities totaled approximately $318.1M as of December 31, 2025, and the company reported a net loss of $105.04M for the year.
The company’s BLA for deramiocel in Duchenne muscular dystrophy remains under FDA review with a PDUFA target action date of August 22, 2026, supported by the HOPE-3 Phase 3 trial that met its primary and key secondary cardiac endpoints. Late-breaking HOPE-3 data presented at MDA 2026 showed additional cardiac and functional benefits, its San Diego GMP facility is operational for potential commercial launch, and the StealthX exosome-based vaccine Phase 1 trial is ongoing with final results expected in the second quarter of 2026. Capricor also completed an uplisting to the Nasdaq Global Select Market and expects its cash balance to support operations through 2027.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $22M | $50M | $11M+ $140M short-term inv. | $10M-$40M operating cash flow | report ↗ |
| 2023-FY | $25M | $36M | $15M+ $25M short-term inv. | $5.6M-$26M operating cash flow | report ↗ |
| 2022-FY | $2.5M | $22M | $9.6M+ $32M short-term inv. | $7.3M$4.9M operating cash flow | report ↗ |
| 2021-FY | $0.2M | $14M | $35M+ $0 short-term inv. | $5.0M-$17M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 13 sales ($8.4M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-06-25 | Bergmann Anthony · CHIEF FINANCIAL OFFICER | Option exercise | 24,100 | $3.18 | $77K | Form 4 |
| 2026-06-25 | Krasney Karen · EVP, GENERAL COUNSEL | Option exercise | 24,100 | $3.18 | $77K | Form 4 |
| 2026-06-25 | Bergmann Anthony · CHIEF FINANCIAL OFFICER | Open-market sale | 24,100 | $30.38 | $732K | Form 4 |
| 2026-06-25 | Krasney Karen · EVP, GENERAL COUNSEL | Open-market sale | 24,100 | $30.38 | $732K | Form 4 |
| 2026-06-25 | Bergmann Anthony · CHIEF FINANCIAL OFFICER | Option exercise (derivative) | 24,100 | — | — | Form 4 |
| 2026-06-25 | Krasney Karen · EVP, GENERAL COUNSEL | Option exercise (derivative) | 24,100 | — | — | Form 4 |
| 2026-06-24 | Bergmann Anthony · CHIEF FINANCIAL OFFICER | Option exercise | 400 | $3.18 | $1K | Form 4 |
| 2026-06-24 | Krasney Karen · EVP, GENERAL COUNSEL | Option exercise | 400 | $3.18 | $1K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 177 reporting institutions held 33.9M shares ($1.0B, 58.2% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | SUVRETTA CAPITAL MANAGEMENT, LLC | 3,818,600 | $116.1M |
| 2 | BlackRock, Inc. | 3,421,815 | $104.0M |
| 3 | TANG CAPITAL MANAGEMENT LLC | 3,399,900 | $103.4M |
| 4 | STATE STREET CORP | 2,181,901 | $66.3M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 2,027,732 | $61.6M |
| 6 | RA CAPITAL MANAGEMENT, L.P. | 1,507,844 | $45.8M |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 1,118,326 | $34.0M |
| 8 | GOLDMAN SACHS GROUP INC | 911,976 | $27.7M |
| 9 | Jones Hill Capital LP | 909,207 | $27.6M |
| 10 | Point72 Asset Management, L.P. | 821,179 | $25.0M |
| 11 | FMR LLC | 772,649 | $23.5M |
| 12 | Boxer Capital Management, LLC | 590,000 | $17.9M |
| 13 | JANE STREET GROUP, LLC | 566,081 | $17.2M |
| 14 | J. Goldman & Co LP | 541,522 | $16.5M |
| 15 | CITADEL ADVISORS LLC | 539,232 | $16.4M |